Hemady Shortage: What Providers and Prescribers Need to Know in 2026

Hemady (dexamethasone) 20 mg tablets are not currently listed on the FDA Drug Shortage Database, but that fact offers little comfort to oncology providers whose patients are calling in frustrated because their Hemady prescription can't be filled. The reality is that Hemady's specialty-only distribution model, combined with payer prior authorization requirements, creates genuine access friction for patients — and that friction often lands on your clinic to resolve. This article provides a concise, evidence-informed overview for hematology/oncology providers on the current state of Hemady access, workflow strategies to minimize delays, and guidance on dexamethasone alternatives when Hemady cannot be obtained.

Current Hemady Availability Status (2026)

As of early 2026, Hemady 20 mg oral tablets are not in an official FDA shortage. The manufacturer, Edenbridge Pharmaceuticals (also operating as Dexcel Pharma), continues to produce and supply Hemady through specialty pharmacy distribution channels. Supply appears stable nationally. Patient access problems in 2026 are primarily driven by:

• Specialty-only distribution: Hemady is not stocked at most retail pharmacies; patients must use specialty or hospital pharmacies
• Payer prior authorization requirements: Most commercial plans and Medicare Part D require PA for Hemady; denials and appeals cause delays
• Patient unawareness: Patients who take their prescription to a retail pharmacy are told it isn't carried, which they interpret as a shortage
• Note — distinguish from IV shortage: Dexamethasone sodium phosphate injection (IV) is in an active FDA shortage in 2026; this affects hospital settings and is separate from Hemady oral tablets

Prescribing Workflow Recommendations to Minimize Patient Access Delays

The following workflow modifications can significantly reduce the frequency of patient calls and treatment delays related to Hemady access:

1. Route Prescriptions Directly to Specialty Pharmacies

Always send Hemady prescriptions directly to a specialty pharmacy rather than giving the patient a paper prescription. Establish a preferred specialty pharmacy relationship (CVS Specialty, Walgreens Specialty, Accredo, Biologics by McKesson, Optum Specialty) and use electronic prescribing or direct fax. This prevents the patient from going to a retail pharmacy that doesn't stock the medication.

2. Initiate Prior Authorization at the Time of Prescribing

The most common source of Hemady delays is PA not being in place. Initiate the PA at the time of first prescribing, and set a calendar reminder to renew it before it expires (many plans require annual renewal). Your specialty pharmacy partner can often assist with PA submission and tracking. Document the following in your PA request:

• Multiple myeloma diagnosis (ICD-10: C90.0x)
• The specific anti-myeloma combination regimen being used (e.g., VRd, KRd, DRd)
• Rationale for Hemady specifically (pill burden reduction, FDA-approved indication for this use)
• Number of tablets per dose and frequency

3. Have a Documented Bridge Protocol for Hemady Access Failures

Document in your practice's protocol that generic dexamethasone 4 mg tablets may be prescribed as a bridge if Hemady is temporarily unavailable. This allows clinic staff to issue bridge prescriptions without requiring an individual attending decision for each case. Patients should be counseled in advance that if Hemady is not available, they may temporarily use the equivalent dose of generic dexamethasone 4 mg tablets at the same schedule.

Dexamethasone Alternatives When Hemady Cannot Be Obtained

The clinical evidence base for dexamethasone in multiple myeloma regimens is specific to dexamethasone — not other corticosteroids. Standard myeloma regimens (VRd, KRd, Rd, DRd, PD, etc.) were developed and validated with dexamethasone. Substitution with another corticosteroid is generally not recommended unless there is a specific contraindication or intolerance to dexamethasone. Options in order of preference:

1. Generic dexamethasone 4 mg tablets (preferred bridge): Same active ingredient; widely available; calculate equivalent dose (e.g., 40 mg = ten 4 mg tablets). Evidence-equivalent; only the dosing convenience differs.
2. Dexamethasone oral solution: Available for patients with swallowing difficulties or GI issues. Requires precise dose calculation (1 mg/mL concentration; e.g., 40 mL for a 40 mg dose).
3. Prednisone (rarely, in specific clinical situations): Some older literature and small series support prednisone in elderly or frail patients who are particularly intolerant of high-dose dexamethasone. This is an individualized clinical decision, not a routine substitution. Potency conversion: dexamethasone 40 mg ≈ prednisone 250 mg (note: impractical at standard tablet dosing; prednisone substitution typically involves lower, modified regimens designed specifically for frail patients).

Informing Patients and Managing Expectations

Proactively counsel your Hemady patients at first prescribing: explain that Hemady is a specialty medication, not available at retail pharmacies, and that they should expect their prescription to go through a specialty pharmacy. Set expectations that the first fill may take a few days to a week due to PA processing. Direct them to medfinder for Providers to help locate pharmacies in their area that can fill Hemady, so your clinic isn't fielding every call about where to fill it.

Key Takeaways for Providers

• Hemady 20 mg oral tablets are not in FDA shortage in 2026; access issues are structural, not supply-driven
• Always e-prescribe directly to a specialty pharmacy — never give a paper Rx that a patient might take to a retail pharmacy
• Initiate prior authorization at the time of first prescribing and track renewal dates
• Have a documented bridge protocol using generic dexamethasone 4 mg tablets for short-term access gaps
• The Hemady Patient Savings Program (1-866-651-4128) can reduce cost to $0 for commercially insured patients — share this resource
• IV dexamethasone injection is in a separate shortage in 2026; monitor availability for inpatient uses independently